Agile Therapeutics, Inc. Announces Full Exercise of Option to Purchase Additional Shares by Underwriters
05 2월 2016 - 6:10AM
Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty
pharmaceutical company focused on the development and
commercialization of new prescription contraceptive products, today
announced that the underwriters of its previously announced public
offering of common stock have exercised in full their option to
purchase an additional 826,771 shares of Agile Therapeutics’ common
stock. The additional shares were sold at the public offering price
of $6.35 per share before underwriting discounts and
commissions. The closing occurred on February 4, 2016,
bringing the total number of shares sold by Agile Therapeutics in
the public offering to 6,338,583 and total gross proceeds to
approximately $40.25 million. The total net proceeds after
deducting underwriting discounts and commissions and estimated
offering expenses, are expected to be approximately $37.3 million
from the offering.
William Blair and RBC Capital Markets acted as
joint book-running managers for the offering. In addition,
Janney Montgomery Scott, Cantor Fitzgerald & Co., and
FBR acted as co-managers.
The shares of common stock described above are
being offered by Agile Therapeutics pursuant to its shelf
registration statement on Form S-3 previously filed and declared
effective by the Securities and Exchange Commission. The
offering is being made only by means of a prospectus supplement and
the accompanying prospectus, copies of which may be obtained from
William Blair & Company, L.L.C., Attention: Prospectus
Department, 222 West Adams Street, Chicago,
IL 60606; Telephone: (800) 621-0687 or by email
at prospectus@williamblair.com and RBC Capital Markets, LLC,
200 Vesey Street, 8th Floor, New York, NY 10281-8098;
Attention: Equity Syndicate; Tel: (877) 822-4089; email:
equityprospectus@rbccm.com.
This press release shall not constitute an offer to
sell or a solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Agile Therapeutics, Inc.Agile
Therapeutics is a women's health specialty pharmaceutical company
focused on the development and commercialization of new
prescription contraceptive products. Our product candidates are
designed to provide women with contraceptive options that offer
greater convenience and facilitate compliance. Our lead product
candidate, Twirla®, (ethinyl estradiol and levonorgestrel
transdermal system), also known as AG200-15, is a once-weekly
prescription contraceptive patch currently in Phase 3 clinical
development. Twirla is based on our proprietary transdermal patch
technology, called Skinfusion®, which is designed to provide
advantages over currently available patches and is intended to
optimize patch adherence and patient acceptability.
Forward-Looking StatementCertain
information contained in this press release includes
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995, including statements
related to our public offering and potential market opportunity for
our product candidates. We may, in some cases use terms such as
"predicts," "believes," "potential," "continue," "anticipates,"
"estimates," "expects," "plans," "intends," "may," "could,"
'might," "will," "should" or other words that convey uncertainty of
the future events or outcomes to identify these forward-looking
statements. Our forward-looking statements are based on current
expectations that involve risks, potential changes in
circumstances, assumptions and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong, or be affected
by inaccurate assumptions we might make or by known or unknown
risks and uncertainties as a result of various important factors,
including the uncertainties related to market conditions and the
completion of the public offering on the anticipated terms or at
all and such other factors. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to our business in general, please refer to our
prospectus supplement filed with the Securities and Exchange
Commission (SEC) on January 22, 2016 under the heading “Risk
Factors” and those documents incorporated by reference therein,
which includes our Quarterly Report on Form 10-Q filed with the SEC
on November 9, 2015. You are cautioned not to place undue reliance
on these forward-looking statements, which are made only as of the
date of this press release. We undertake no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Contact: Mary Coleman -- 609-356-1921
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024